Do Borrelia IgM antibodies require clinical context to interpret?

Borrelia (Lyme disease) serology is most informative when aligned with illness timing and a compatible clinical syndrome. IgM is an early antibody response, but neither its presence nor its absence alone reliably determines whether infection is currently active.

Clinical evidence

• In erythema migrans cohorts, antibody detection rises over the first weeks of illness: 43% had positive IgM immunoblots at baseline, increasing to 91% by 8–14 days when ELISA and/or IgM immunoblot results were considered. In another cohort, two-tier IgM-or-IgG positivity rose from 29% in acute samples to 64% at 3–4 weeks.
• Thus, early seronegativity can occur in genuine infection, while later isolated IgM is diagnostically problematic. CDC-aligned and IDSA/AAN/ACR guidance advise disregarding IgM for illness lasting >30 days and relying on IgG-based interpretation.

Persistence, cross-reactivity, and mechanisms

• Antibodies can remain detectable after resolved infection. Ten to twenty years after prior Lyme disease, IgM was detectable in 10% of people with prior early Lyme disease and 15% with prior Lyme arthritis, despite no clinical evidence of active disease; IgM immunoblot positivity has also been reported in 38% at one year.
• False-positive IgM can result from cross-reactivity, including during acute Epstein–Barr virus or CMV infection and in association with rheumatoid factor. Reactivity to individual Borrelia antigens such as OspC, OspB, or VlsE does not eliminate this possibility.

Clinical implications

• The predictive value of isolated IgM depends strongly on pretest probability. In a low-incidence North Carolina cohort, only 8/53 (15%) IgM-only positive patients had compatible active Lyme disease; overall serology positive predictive value was 17%, falling to 10% without travel to an endemic area.

Bottom line

• Borrelia IgM usually develops before IgG but over days to weeks, may persist after resolved disease, and may cross-react. It should be interpreted with symptom duration, compatible manifestations, exposure likelihood, and validated two-tier testing—not as stand-alone evidence of active infection.